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Background. Pten functionally acts as a tumor suppressor gene. Lately, tissue-specific ablation of Pten gene in mice has
elucidated the role of Pten in different tumor progression models. However, a temporally controlled Pten loss in all adult
tissues to examine susceptibility of various tissues to Pten-deficient tumorigenesis has not been addressed yet. Our goal was
to explore the genesis of Pten-deficient malignancies in multiple tissue lineages of the adult mouse. Methods and Findings.
We utilized an inducible Cre/loxP system to delete Pten exon 5 in the systemic organs of ROSA26 (R26)-CreER
T;Pten
fx/fx mice.
On reaching 45 weeks 4OHT-induced Pten loss, we found that the R26-CreER
T;Pten
fx/fx mice developed a variety of
malignancies. Overall tumor mean latency was 17 weeks in the Pten-deficient mice. Interestingly, mutant females developed
malignancies more quickly at 10,11 weeks compared with a tumor latency of 21 weeks for mutant males. Lymphoma
incidence (76.9% in females; 40.0% in males) was higher than the other malignancies found in the mutant mice. Mutant males
developed prostate (20.0%), intestinal cancer (35.0%) and squamous cell carcinoma (10.0%), whereas the mutant females
developed squamous cell carcinoma (15.4%) and endometrial cancer (46.1%) in addition to lymphomas. Furthermore, we
tested the pharmacological inhibition of the PTEN downstream effectors using LY294002 on Pten-deficient prostate
hyperplasia. Our data revealed that, indeed, the prostate hyperplasia resulting from the induced Pten loss was significantly
suppressed by LY294002 (p=0.007). Conclusions. Through monitoring a variety of Pten-deficient tumor formation, our results
revealed that the lymphoid lineages and the epithelium of the prostate, endometrium, intestine and epidermis are highly
susceptible to tumorigenesis after the Pten gene is excised. Therefore, this R26-CreER
T; Pten
fx/fx mouse model may provide an
entry point for understanding the role of Pten in the tumorigenesis of different organs and extend the search for potential
therapeutic approaches to prevent Pten-deficient malignancies.
Citation: Lu T-L, Chang J-L, Liang C-C, You L-R, Chen C-M (2007) Tumor Spectrum, Tumor Latency and Tumor Incidence of the Pten-Deficient
Mice. PLoS ONE 2(11): e1237. doi:10.1371/journal.pone.0001237
INTRODUCTION
Tumors occur in normal tissues that are challenged by a variety of
genetic and environmental risk factors. These risk factors may
consequently evoke aberrant effects on cytoplasmic signaling
network, which result in uncontrolled cellular proliferation, cell
survival and heterotypic cross-talk with neighboring cells. Among
the various types of complicated cellular signaling circuitry that
have been identified, the tumor suppressor PTEN, a phosphatase
and tension homolog on chromosome 10, acts as the most
important negative regulator of the phosphatidylinositol 3-kinase
(PI-3K) signaling pathway [1,2]. PTEN converts PIP3 to
phosphatidylinositol (4,5) diphosphate (PIP2) in order to maintain
a homeostasis of PIP3, which is generated by PI-3K activation [3].
Inactivation of PTEN results in an accumulation of PIP3, which
recruits the serine/threonine kinase PKB/AKT to the cell
membrane and this further activate downstream of the PI-3K/
AKT signaling pathway to promote cellular proliferation, anti-
apoptosis, cell survival and tumorigenesis [1,4].
Mutation of PTEN is often seen in human cancers [5,6,7]. Using
a gene targeting strategy to ablate Pten gene function in the mouse
causes embryonic lethality between days 6.5 to 9.5 of gestation
[8,9,10,11]. The early lethality of Pten-deficient mice limits our
understandingregardinghowPTENregulatesdownstreamsignaling
and is related to tumorigenesis at adult stage. Up to this point, mice
heterozygous for Pten have provided some basis for study because
they develop a variety of cancers, including breast cancer,
endometrial cancer, prostate tumors and lymphoma [8,9,11,12].
Loss-of-heterozygosity of Pten might contribute to the tumor
development in Pten
+/2 mice[9,11,12]. In addition, other genetic
lesions such as Nkx3.1, Trp53 or p27KIP1 might be involved in
decreasing latency and increasing invasiveness/metastasis during
tumor development in Pten
+/2 mice [13,14,15,16,17].
Using Cre-loxP conditional genetics [18,19], tissue-specific
inactivation of Pten results in tumor formation in the targeted
tissues of the mouse. Prostate-specific ablation of loxP-flanked Pten
gene (Pten
fx/fx) utilizing different Cre transgenic mice lines such as
probasin-Cre, prostate-specific antigen (PSA)-Cre or mouse mam-
mary tumor virus (MMTV)-Cre has shown the occurrence of
prostate cancer progression similar to that which occurs in humans
[20,21,22,23]. Likewise, conditionally ablating the Pten gene in
hematopoietic lineages causes various leukemias in the mouse
[24]. Such Cre activity might also be present in the disease-
initiating stem cells from which the Pten gene is deleted, which is
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[24,25,26]. Thus, tissue-specific and cell type-specific Pten
knockout mice have provided a fundamental basis for an
understanding of the role of Pten in different tumor progression
models. However, somatic inactivation of Pten in a temporally
controlled manner in all adult tissues to test susceptibility of
various tissues to Pten-deficient tumorigenesis has not been carried
out up to the present.
To assess the tumor incidence, latency and spectrum of Pten-
deficient adult mice, we utilize two mouse strains: firstly, the
ROSA26 Cre-estrogen receptor (R26-CreER
T) knock-in mouse line,
which expresses inducible Cre recombinase driven by the ubiquitous
promoter ROSA26 [27] and secondly, the Pten
fx/fx mouse carrying
loxP-flanked exon 5 encoding the phosphatase domain of PTEN
[28,29].4-hydroxytamoxifen(4-OHT)isadministratedtoinducethe
Pten gene excision in a temporally controlled manner in the crossed
mutant offspring (R26-CreER
T/+;Pten
fx/fx). In this report, we found
that lymphoid lineages, the squamous epithelium of the epidermis,
the simple epithelium of the prostate, the endometrium and the
intestine are highly susceptible to tumorigenesis in such a Pten-
deficient background. Application of the PI3K inhibitor LY294002
in these Pten-deficient mice resulted in the enlargement of the
anterior prostate glands being significantly suppressed. Thus, we
have established a Pten-deficient tumor model, which demonstrates
that multiple cell lineages can be provoked to undergo aberrant
cellular signaling simultaneously and that this results in major
changes of normal tissues.
RESULTS
Temporally controlled CreER-mediated
recombination by 4OHT administration
The inducible Cre activity of the R26-CreER
T transgenic mice was
demonstrated in neuronal tissues by Badea et al. [27]. In this
report, we have examined temporally controlled Cre activity in the
systemic organs of R26-CreER
T; R26R bigenic mice. After 4OHT
treatment for one week, whole mount X-gal staining revealed that
the 4OHT-induced b-galactosidase expression showed focal or
mosaic blue patterns in the brain, liver, pancreas, kidney, intestine,
uterus and bladder of R26-CreER
T;R26R bigenic males or females
(Figure 1). Non-specific X-gal staining was also observed in the
hind-stomach, the gut, the prostate and the vas deferens (Figure 1
and data not shown). These results suggested that the inducible
Cre activity of R26-CreER
T transgenic mice had been successfully
controlled by 4OHT in a variety of organs, although the level of
inducible Cre activity may have differed as indicated by the
variable X-gal stained intensity among these systemic organs.
To investigate tumor susceptibility in the Pten-deficient mice at
an adult stage, we generated R26-CreER/+;Pten
fx/fx (referred to
as R26-Pten
fx/fx hereafter) and control (R26-Pten
fx/+, Pten
fx/+ or
Pten
fx/fx) mice and followed this with 4OHT induced Cre/loxP
recombination to excise exon 5 of Pten gene (Figure 2A). After
4OHT treatment for one week, we examined the efficiency of
exon 5 of Pten gene excision using the genomic PCR method in
a variety of organs dissected from males and females carrying the
Pten
fx/+, R26-Pten
fx/+ and R26-Pten
fx/fx genotypes (Figure 2B). Our
result showed that exon 5 of the Pten gene excision was detected in
R26-Pten
fx/+ and R26-Pten
fx/fx tissues, indicating that 4OHT was
able to induce Cre-mediated excision of loxP-flanked region in the
tissues examined (Figure 2B). Notably, the excision efficiency of
Pten showed no overt differences between males and females
carrying the R26-Pten
fx/+ or R26-Pten
fx/fx genotypes. However,
inducible Cre activity may vary slightly across the organs of the
R26-Pten
fx/+ or R26-Pten
fx/fx mice (Figure 2B). We next examined
the expression of PTEN protein in selected organs, specifically the
anterior prostate and the intestinal tract, of 4OHT-injected R26-
Pten
fx/fx and control (R26-Pten
fx/+) mice using immunofluorescence
microscopy. Our results showed that PTEN could be detected in
the prostate and colon epithelium, which was indicated by
cytokeratin 8 (CK8) staining of the controls (yellow; CK8-positive,
PTEN-positive). In contrast, PTEN expression was lost in most of
the hyperplastic epithelial lesions and tumor lesions (red; CK8-
positive, PTEN-negative) found in the corresponding organs of the
R26-Pten
fx/fx mice (Figure 2C). We also examined the expression
of PTEN in various other systemic organs, namely the lung and
the kidney, of R26-Pten
fx/fx and the control mice to demonstrate
PTEN loss (Figure S1). Our results suggested that the majority of
PTEN was lost from the systemic organs of the R26-Pten
fx/fx mice
(Figure 2B & C; Figure S1).
Analysis of R26-Pten
fx/fx and R26-Pten
fx/+
malignancies
Furthermore, R26-Pten
fx/fx (n=33; 20 males and 13 females) and
control (Pten
fx/fx, n=24; R26-Pten
fx/+, n=21) mice were given 4-
OHT injection (i.p.) at age of 6 weeks and then monitored for
tumor development over about 60 weeks. The mice were
sacrificed for pathological analysis (H&E and IHC) when they
manifested sign of distress or on tumor detection. The cumulated
tumor-free survival curves of the R26-Pten
fx/fx and control mice are
shown in Figure 3A. Our results showed that all the R26-Pten
fx/fx
mice died from their tumor burden by 45 weeks post 4OHT
injection(Table1).TheoverallmeanlatencyofPten-deficienttumor
formation was 17 weeks. In addition, we found 4 R26-Pten
fx/+ mice
(19.0%)developedvariousdifferenttypesoftumorsby60 weekspost
4OHT treatment (Table 1). We found that one R26-Pten
fx/+ mouse
suffered from metastatic lung cancer at 42 weeks, two R26-Pten
fx/+
females developed mammary tumors at 52 and 55 weeks and
another R26-Pten
fx/+ male mouse developed hepatocellular carcino-
ma at 58 weeks (Table 1; Figure S2). No tumors were found in the
control group Pten
fx/fx mice at 60 weeks.
Interestingly, we found that the tumor latency and spectrum of
the Pten-deficient mice exhibited gender differences. Approximate-
ly, 50% R26-Pten
fx/fx males and females had malignant tumors at
21 weeks and between 10 and 11 weeks, respectively (Figure 3B).
Most R26-Pten
fx/fx females quickly developed lymphomas (10 of 13;
76.9%) and died at about 9 weeks post-4OHT injection compared
to a much lower incidence of lymphoma formation (8 of 20; 40%)
by 13 weeks in the males (Figure 3C). The Pten-deficient male
mice developed intestinal cancers (7 of 20, 35%) arising from the
colorectum (n=6) and small intestine (n=1), whereas no female
mice developed this type of cancer. This might be partly due to the
quick development of the lymphomas, which caused early lethality
before the intestinal cancer could develop in the R26-Pten
fx/fx
females. In addition, the R26-Pten
fx/fx mice developed squamous
cell carcinoma of the epidermis (4 of 33 mice, 12.1%; 2 males,
10% and 2 females, 15.4%), endometrial cancer (6 of 13 females,
46.1%) and prostate cancer (4 of 20 males, 20%) (Figure 3C).
The mean latency of these malignancies is showed in Figure 3D.
The sequential occurrence of the Pten-deficient malignancies was
about 11 weeks for the lymphomas and the endometrial cancer,
about 19 weeks for the prostate cancer and squamous cell
carcinoma and about 30 weeks for the intestinal cancer
(Figure 3D).
The lymphomas mainly arose from the thymus and mesenteric
lymph nodes. A representative thymic lymphoma is shown grossly
in Figure 4A. H&E staining revealed a mature appearance for the
small lymphocytic cells and a loss of cortical-medullary architec-
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PLoS ONE | www.plosone.org 2 November 2007 | Issue 11 | e1237Figure 1. Evaluation of 4OHT-induced Cre recombination in R26CreER
T; R26R mice. After 10 days of 4OHT or vehicle control (DMSO) injection, LacZ
reporter activity in the systemic organs including brain, liver, spleen, pancreas, kidney, intestine and reproductive tracts of R26CreER
T;R26R mice (2
males and 2 females) were examined by X-gal staining and compared with those of the control mice. The representative X-gal staining patterns in the
systemic organs of a DMSO-treated control male mouse and the reproductive organs of a control female mouse are shown in the left panels.
Representative X-gal positive (blue) patterns reflecting inducible Cre activity are shown in the other panels (middle, 4OHT-treated R26CreER
T;R26R
female; right, 4OHT-treated R26CreER
T;R26R male). A, adrenal gland; AP, anterior prostate; B, bladder; O, ovary; Ov, oviduct; SV, seminal vesicle; U,
uterus; VD, vas deferens
doi:10.1371/journal.pone.0001237.g001
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PLoS ONE | www.plosone.org 3 November 2007 | Issue 11 | e1237Figure 2. Temporally controlled Pten loss in R26-CreER
T/+;Pten
fx/fx mice. (A) Illustration of Pten conditional (floxed; fx) allele, ROSA26-CreER
T
transgene and 4OHT-induced Pten exon 5 excision. The CreER
T fusion protein (inactive) was initially expressed under a ubiquitous promoter ROSA26.
The 4OHT inducer was used to temporally active the CreER
T recombinase activity, which resulted in the excision of the DNA fragment containing the
Pten exon 5. (B). PCR genotyping of the Pten floxed allele and Cre-mediated exon 5 excision; After one week of 4OHT injection, genomic DNA was
isolated individually from multiple organs including the lung, the liver, the intestine, the kidney, the spleen, the thymus, the tail, the anterior prostate
and the uterus of mice carrying different genotypes (C, Pten
fx/+;1 ,R26-Pten
fx/+ male; 2, R26-Pten
fx/+ female; 3, R26-Pten
fx/fx male; 4, R26-Pten
fx/fx female).
PCR genotyping is shown that allows the identification of the Pten floxed allele (,1100-bp), the wild-type (,1000-bp) and the exon 5 excised alleles
(D5; ,400-bp) from the 4OHT-treated mice. (C). Immunostaining of PTEN in the prostate and the colon. Representative merged images of the
immunofluorescence analysis reveal the expression level of PTEN in the anterior prostate lobe (at 7 weeks post-4OHT treatment) and the colon (at
37 weeks post-4OHT treatment) of the R26-Pten
fx/+ and R26-Pten
fx/fx mice. Antibody against PTEN (green) and TROMA-I antibody against cytokeratin 8
(CK8; red) were used to study the expression of PTEN in the simple epithelial subsets. Arrows indicated the coexpression of PTEN and CK8 (yellow) in
anterior prostate gland and colon epithelium of R26-Pten
fx/+ mice (left panels), whereas the hyperplastic epithelial subsets (middle panels; red) of the
R26-Pten
fx/fx mice showing PTEN loss (arrowheads). In addition, the immunofluorescence images in the right panels reveal PTEN loss in the tumor
lesions of prostate and colon of R26-Pten
fx/fx males (at 13 and 39 weeks, respectively). Scale Bar, 200 mm.
doi:10.1371/journal.pone.0001237.g002
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PLoS ONE | www.plosone.org 4 November 2007 | Issue 11 | e1237ture in this thymic tumor (Figure 4A). To verify the potential
origins of this lymphoma, T-cell and B-cell origins were
respectively determined by antibodies against CD3 and B220 in
the liver with the infiltrated lymphoid tumor cells in the portal area
identified using IHC, which showed that this tumor was a CD3-
positive T-cell lymphoma (Figure 4B). Through evaluation of
CD3 and B220 expression in the lymphomas formed in the
mutant mice, we found that all lymphomas were derived from
CD3-positive T-cells with either a mature appearance of small
lymphocytes or large lymphoblasts (data not shown). Occasionally,
the more detail surface markers that were expressed on these
lymphomas were analyzed by flow cytometry in order to assist our
verification of these lymphomas. As an example, a CD4-rich T-cell
lymphomas was found to have developed in a R26-Pten
fx/fx mouse
Figure 3. Tumor-free survival, tumor spectrum and tumor incidence of R26-Pten
fx/fx mice. (A) Tumor-free survival of Pten
fx/fx, R26-Pten
fx/+ and R26-
Pten
fx/fx mice; (B) Tumor-free survival of male and female R26-Pten
fx/fx mice; (C) Tumor spectrum and incidence of male and female R26-Pten
fx/fx mice;
Lym, lymphomas; PC, prostate cancer; EC, endometrial cancer; IC, intestinal cancer; SCC, squamous cell carcinoma; The percentage of each tumor
type is shown on the right of bar graph. (D) Tumor latency of the R26-Pten
fx/fx mice; each dot represents an individual malignant tumor in the R26-
Pten
fx/fx mice. X, Lymphoma (Lym); &, Squamous cell carcinoma (SCC); m, Intestinal cancer (IC); N, prostate cancer (PC); Bars represent the mean
tumor latency.
doi:10.1371/journal.pone.0001237.g003
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mouse developed both CD4- and CD8-rich lymphomas arising
from the thymus and mesenteric lymph node, respectively,
suggesting that 4OHT-induced Pten loss in different lymphoid
origins may develop simultaneously (data not shown).
In addition to lymphomas, prostate cancer, endometrial cancer,
intestinal cancer and squamous cell carcinoma of the epidermis
were found in R26-Pten
fx/fx mice using H&E and IHC analyses
(Figures 3 & 5). The focal invasions of the prostate, endometrial
and colorectal carcinomas were observed and characterized by
H&E or IHC using antibodies against E-cadherin (Figure 5). Pre-
cancer lesions (hyperplasia/dysplasia and adenoma) of correspond-
ing malignancies were also observed in the R26-Pten
fx/fx mice
(Figure 6). We found that R26-Pten
fx/fx males had developed small
or large intestinal polyps at late onset (.35 weeks; Figure 6A & B).
Inaddition,mostmutantfemalesdeveloped endometrialhyperplasia
(7 of 13) at between 7 and 9 weeks post-4-OHT injection
(Figure 6C). The early alternations associated with prostate
hyperplasia (BPH) or prostate intraepithelial neoplasm (PIN) were
observed at 4,6 weeks post 4-OHT injection (Figure 6D).
Moreover, multiple tumors were also observed in R26-Pten
fx/fx
mice (9 of 33, 27.3%; 5 females and 4 males). Among these
animals, all females developed T-cell lymphoma and endometrial
cancer at 7,23 weeks post-4OHT injection. One of these females
also developed squamous cell carcinoma additionally. Furthermore,
two males developed prostate cancer together with lymphoma (at
13 weeks) and colorectal cancer (at 27 weeks), respectively. Finally,
two males developed squamous cell carcinomas and colorectal
cancer at 28 and 31 weeks post-4OHT injection.
Temporally controlled prostate tumorigenesis
The advantage of the use of inducible CreER
T/loxP technology in
this report is that it allowed the monitoring of tumor development
at specific time points after 4-OHT injection. To investigate the
progression of Pten-deficient malignancies, prostate cancer pro-
gression was chosen as the initial model because a good
understanding of the role of Pten in this disease has been gained
from other prostate-specific Pten knockout mouse model studies
[20,21,23,25]. At 4 weeks, 6 weeks and 30 weeks after 4-OHT
injection, we found gradually enlargement of the anterior prostate
in R26-Pten
fx/fx mice compared to the controls (Figure 7A).
Histologically, these prostate lesions were studied at the above time
points (4, 6 and 30 weeks) and this revealed the prostate cancer
progression through BPH/PIN to invasive cancer (Figure 7A).
We then determined activation of AKT using antibody against
phosphorylated AKT (p-AKT-Ser473) specifically. We found that
AKT phosphorylation appeared in all prostate lesions along with
hyperplasia and neoplasia in the R26-Pten
fx/fx mice, unlike the
controls (Figure 7B). To identify the potential cell type of the Pten-
deficient prostate cancer, we performed double immunofluorescent
staining to verify the presence of cytokeratin 5 (CK5
+)-expressing
basal cells and cytokeratin 8 (CK8
+)-expressing lumen epithelial cells
from the normal, BPH, PIN and prostate cancer samples inthe R26-
Pten
fx/fx mice compared with the controls. Flattened and discontin-
uous CK5
+-expressing cells were observed underneath the CK8
+-
expressing lumen epithelium in the control prostate, whereas
stratification of the CK8
+ lumen epithelium together with flatten
CK5
+ basal cells were noticed in the BPH/PIN lesions (Figure 7C).
As the disease progressed to invasive prostate cancer in the R26-
Pten
fx/fx males, focal expansion of the CK5
+ cells and coexpression of
the CK5
+/CK8
+ cells were significantly increased (Figure 7C).
However, the significance of the increased CK5/CK8 double
positive cells in the Pten-deficient prostate cancer remains unclear.
The PI3K inhibitor, LY294002, suppresses prostate
hyperplasia
We next evaluated the effect of the potential cancer targeting
agent LY294002, which is a potent inhibitor of PI3K-AKT
signaling pathway in Pten-deficient prostate tumor progression. After
LY294002 treatment for 4 weeks, we found that the apparent
increased anterior prostate weight in R26-Pten
fx/fx mice (n=4) was
significantly suppressed (p=0.007) in comparison to the controls
(LY294002-treated Pten
fx/fx mice, n=3; vehicle-treated R26-Pten
fx/fx
mice,n=3;Figure8A).HistologicalH&Estainingrevealedthatthe
increased cellularity and nuclear atypia of the anterior prostate were
diminished in LY294002 treated R26-Pten
fx/fx mice compared with
the untreated mice (Figure 8B). We next examined whether
LY294002 treatment blocked the PI3K-AKT signaling pathway.
Using IHC, we found that only focal epithelial lesions showed
pAKT(Ser473)-positive staining in LY294002 treated R26-Pten
fx/fx
prostates, suggesting that LY294002 treatment strongly suppresses
AKT phosphorylation at Ser473 in R26-Pten
fx/fx mice compared to
the untreated animals (Figure 8B). Therefore, our results
demonstrated that inhibition of the PI3K-AKT pathway was
sufficient to suppress Pten-deficient prostate hyperplasia.
DISCUSSION
In this study, we demonstrated that the tumor spectrum, tumor
incidence and tumor latency during temporally controlled Pten loss
in the mouse. This is the first in vivo analysis of Pten-deficient
tumorigenesis in the systemic organs of the adult mouse. It is likely
that lymphoid lineages and the epithelium of the prostate,
endometrium, intestine and epidermis are highly susceptible to
tumorigenesis after the Pten gene is excised by 4OHT-induced
Cre/loxP recombination in the mouse’s adult tissues. Although we
have observed that Cre-mediated Pten excision did slightly vary
among the systemic organs of R26-Pten
fx/+ or R26-Pten
fx/fx mice,
the variation seemed to show no correlation with the occurrence of
Pten-deficient malignancies. Neoplastic cells may initiate from
a single cell or a small number of cells because they are highly
susceptible to tumorigenesis after PTEN loss and therefore slight
variations in the Cre-mediated Pten excision will not affect the
presence of such foci. Clinical studies have shown that somatic
Table 1. Malignancies of R26-Pten
fx/+ and R26-Pten
fx/fx mice
......................................................................
R26-Pten
fx/+ R26-Pten
fx/fx
Total number 21 33
Male 16 20
Female 5 13
Tumor incidence (%) 4 (19.1) 33 (100.0)
Tumor spectrum (%)
Lymphoma 0 18 (46.2)
Lung cancer 1 (25.0) 0
Liver cancer 1 (25.0) 0
Intestinal cancer 0 7 (17.9)
Prostate cancer 0 4 (10.3)
Endometrial cancer 0 6 (15.4)
Breast cancer 2 (50.0) 0
Squamous cell carcinoma 0 4 (10.3)
Total tumor number 4 39
*
*Multiple tumors were found in R26-Pten
fx/fx mice (5 females and 4 males).
doi:10.1371/journal.pone.0001237.t001
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PLoS ONE | www.plosone.org 6 November 2007 | Issue 11 | e1237alterations of PTEN are found in proximately 5% of lympho-
mas[30], 29% of prostate cancer [31] and 34% of endometrial
cancer [32]. Moreover, germline PTEN mutation shows strong
linkage to Cowden syndrome (CS) and Bannayan-Zonana
syndrome (BZS). These are inherited tumor predisposition
syndromes in which hamartomas may develop in the central
nervous system, gastrointestinal tract, skin, breast and thyroid
[33]. Affected individuals of CD families also have a higher risk of
malignancy in corresponding tissues [33,34,35]. Thus, our findings
for the R26-Pten
fx/fx tumor malignancies resemble to some degree
of the tumor spectrum observed in human PTEN genetic studies.
Interestingly, the tumor latency and tumor spectrum of R26-
Pten
fx/fx mice exhibit gender-bias. Pten-deficient females are
predisposed to lymphoma with an early onset of about 7 weeks,
which may preclude the formation of other malignancies; the
result of this may be the overall gender differences in the tumor
spectrum. Particularly, intestinal cancer was not observed in Pten-
deficient females, which may partly be due to the longer period
time required to develop intestinal cancer, namely 25 weeks to
35 weeks post 4OHT treatment in mutant male mice.
Furthermore, we observed that only four mice heterozygous for
the Pten floxed allele, among 21 R26-Pten
fx/+ mice analyzed,
developed a variety of malignancies (up to 60 weeks).The incidence
(19.0%, 4 of 21), latency (42 to 58 weeks) and spectrum (lung, breast
and liver cancers) of the malignant tumors in our R26-Pten
fx/+ miceis
quite different from that of a previous reported Pten
+/2 mouse model
[9]. This report described approximately 18% lymphomas, 22%
uterine cancer and 49% breast cancer occurring at ages ranging
from26to 65 weeks.Thisdiscrepancymaybeexplainedbythe focal
or mosaic excised activity of Cre/loxP-mediated recombination in
the R26-Pten
fx/+ mice. In addition, it is possible that the genetic
background of the two mouse models or some other undefined
mechanism may affect the tumor latency and spectrum between the
different mouse models of Pten heterozygosity [8,11,12,36]. In
a previous study, Freeman et al. reported that tumorigenesis in Pten
heterozygotes was strongly affected by the genetic background of the
Figure 4. Characterization of R26-Pten
fx/fx lymphomas. (A) Gross morphology of a R26-Pten
fx/fx thymic tumor enlarged compared to the control (ctrl)
thymus. H&E stained section of a R26-Pten
fx/fx thymic tumor reveals the morphology of the small lymphocytic cells in comparison to the control (ctrl).
C, cortex; M, medulla; Scale Bar, 200 mm (B) Infiltrated lymphocytic tumor cells (arrows) in the liver of a R26-Pten
fx/fx mouse characterized by H&E (left)
and IHC antibodies against CD3 (middle; positive stained brown cells) and B220 (right; negative stained blue cells), which allow the assessment of the
origin of the tumor. Scale bar, 200m; High-power views of CD3 or B220 IHC are inserted (scale bar, 100 mm). (C) Flow cytometry analysis of thymocyte
suspensions from a control and a R26-Pten
fx/fx mouse stained with antibodies against CD4 and CD8. Percentage of cells is indicated in each quadrant.
doi:10.1371/journal.pone.0001237.g004
Pten-Deficient Tumorigenesis
PLoS ONE | www.plosone.org 7 November 2007 | Issue 11 | e1237mouse [36]. Mutant mice with a 129;C57BL6 background tend to
have a higher incidence of lymphoid and endometrial malignancies.
In contrast, Pten heterozygotes with a 129;BALB/c background
develop prostate cancer more frequently. These findings are
significant because they suggest that there are different modifier(s)
present in different mouse strains that affect tumorigenesis in the
mice after Pten loss. However, it remains unclear currently whether
such background differences or putative modifier(s) are able to
efficiently contribute to tumorigenesis in bi-allelic Pten loss. This
might be further examined by generating R26-Pten
fx/fx mice with
different genetic backgrounds or different mutant strains in the
future.
Although the multiple tumors that occurred simultaneously in
the Pten-deficient mice may have complicated the monitoring of
tumor formation compared to other mouse models that have used
Pten ablation in a tissue-specific manner, our study is able to
provide knowledge that will help an understanding of Pten tumor
suppressor functional requirements in multiple tissue lineages and
cells. In addition, the latency of the different Pten-deficient cancers
provides a valuable time frame for a more detailed dissection in
the future of the downstream effectors of Pten loss using
pharmacological or genetic approaches. In this study, we tested
the pharmacological inhibition of the Pten downstream signaling
cascade using the PI3K inhibitor, LY294002, which has been
demonstrated to suppress tumor outgrowth in xenografted ovarian
tumors and pancreatic cancer cells in the nude mice [37,38].
Recently, Shukla et al showed that LY294002 treatment suppresses
the invasive properties of several human prostate cancer cell lines
[39]. In our study, we found that prostate hyperplasia after
induced Pten loss at an adult stage is suppressed by LY294002. To
our knowledge, this is the first evidence to show tumor inhibitory
activity of LY294002 in spontaneous tumor formation using
Figure 5. R26-Pten
fx/fx epithelial malignancies. Representative histology (middle panels; H&E) and E-cadherin IHC (right panels; E-cad; NovaRed) of
malignant tumors of R26-Pten
fx/fx prostate, uterus, colorectum and skin tissue are showed to compare with the normal corresponding organs (left
panels; H&E) from control mice. Red arrowheads indicated the invasive border of the prostatic, endometrial and colorectal cancers. High-
magnification views of E-cadherin IHC revealing intense membranous staining are shown in the inserted photos (Bars, 100 mm). Bidirectional arrows
indicated the endometrial portions. M, myometrium; E, endometrium; Scale bars, 200 mm.
doi:10.1371/journal.pone.0001237.g005
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have shown that mTOR inhibition effectively suppresses neuronal
hypertrophy, endometrial hyperplasia and leukemia initiation after
tissue-specific Pten loss or in the Pten
+/2 mice [24,40,41]. Likewise,
mTOR inhibition could also be tested in our temporal controlled
Pten-deficient tumor model and this will allow the dissection of
mTOR pathway requirements when Pten is lost in systemic organs.
In summary, we utilized an inducible Cre/loxP system to ablate
Pten in a temporal-specific manner in the adult mouse. Through
the monitoring of tumor spectrum, tumor latency and tumor
incidence in the Pten-deficient mice, our findings provide an entry
point for an understanding the role of Pten in tumorigenesis across
different tissues. Furthermore, these 4OHT-inducible R26CreER
T;
Pten
fx/fx mice will be a useful mouse model that can be used to
identify and study potential therapeutic approaches that will
prevent Pten-deficient malignancies.
MATERIALS AND METHODS
Mice
Pten
fx/fx [28,29], ROSA26 Cre reporter (R26R) [42] and R26-CreER
T
[27] mice were obtained from the Jackson Laboratory (Jackson
Laboratory, Bar Harbor, ME, USA). R26-CreER/+;R26R/+
bigenic mice were generated in order to examine the effect of
inducible Cre activity in the systemic organs. R26-CreER
T/
+;Pten
fx/fx and the control (R26-CreER
T/+;Pten
fx/+ or Pten
fx/fx) mice
were generated in a mixed background (BALB/c;129;C57BL/6)
by crossing Pten
fx/fx and R26-CreER
T mice; this was followed by
crossing R26-CreER
T/+;Pten
fx/+ and Pten
fx/fx mice. Up to five mice
were housed in microisolator cages and provided with autoclaved
food and water in a specific pathogen free colony. The experimental
procedures using animals were in accordance with the guidelines of
InstitutionalAnimalCareandUseCommittee.PCRgenotypingwas
performed according to the standard protocols.
Pharmacologically administration
4-hydroxytamoxifen (4-OHT; Sigma-Aldrich, St. Louis, MO,
USA) was dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich)
at a concentration of 10 mg/ml. 4-OHT solution was emulsified
in sunflower seed oil (Sigma-Aldrich) by vortexing, which was
followed by mixing on a rotator for 4,6 hours. The mice at the
age of 6 weeks were injected intraperitoneally with a dose of 4-
OHT (4,5g per gram body weight) every other day three times.
Similarly, LY294002 (Calbiochem, La Jolla, CA, USA) was
prepared using the same procedure as 4-OHT. For the LY294002
administration, mice were injected intraperitoneally with
LY294002 (4,5g per gram body weight) one week after the
4OHT treatment.
Whole mount X-gal staining
The systemic organs including brain, lung, liver, spleen, pancreas,
lung, kidney, stomach, intestine and reproductive system were
dissected. Organs were fixed transiently with 10% neutral-buffered
formalin for 30 minutes and rinsed with rinse buffer (2 mM MgCl2,
0.1% sodium deoxycholate, 0.2% NP-40, 16 PBS, pH7.3) for
30 minutes. Organs were incubated with X-gal staining solution
(5 mM potassium hexacyanoferrate, 5 mM potassium hexacynofer-
rate trihydrate, 1 mg/ml X-gal in rinse buffer) for 1 hour at 37uCo r
room temperature with gentle agitation until the appearance of blue
coloration and then organs in X-gal staining solution were
transferred to 4uC refrigerator overnight. Finally, stained organs
were post-fixed with neutral-buffered formalin overnight and stored
in 70% ethanol at 4uC or photography examined by stereomicro-
scopy (MZ6, Leica, Germany).
Figure 6. Pre-cancer lesions of R26-Pten
fx/fx mice. (A & B) Representative H&E stained sections revealed the polyps of the small intestine (A) and the
colon (B) of R26-Pten
fx/fx males at 31 and 39 weeks 4OHT post-treatment, respectively. (C) Representative H&E stain revealing complex atypical
hyperplasia of the endometrim was found in a R26-Pten
fx/fx female, which also suffered from lymphoma, at 11 weeks 4OHT post-treatment. M,
myometrium; (D) Representative histology of high grade PIN was found in a R26-Pten
fx/fx male at 7 weeks post 4OHT injection. Arrowheads indicated
the dysplastic epithelial lesions of the intestine (A & B), the uterus (C) and the anterior prostate gland (D) of R26-Pten
fx/fx mice. Scale bars, 200 mm.
doi:10.1371/journal.pone.0001237.g006
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malignancy
The tumor-free survival rate was analyzed using the Kalpan-Meier
method by the SPSS program (SPSS, Inc., Chicago, IL, USA).
Detail analysis of tumor formation has been described previously
[43,44]. Briefly, mice were inspected for illness or tumor formation
twice every week. Normal tissues or tumor samples were isolated
and fixed in 10% neutral-buffered formalin at 4uC overnight.
Subsequently, the samples were embedded in paraffin and further
processed for histopathological studies as described below. Lung,
kidney, liver and enlarged lymph nodes were also isolated to
histologically to be examined for metastasis. If tumors were not
identified by gross examination, then a necropsy was performed.
Diagnosis of tumor malignancy was carried out in consultation
with pathologists. In general, tissue sections stained by hematox-
ylin and eosin (H&E; see below) were examined by light
microscopy (BX51, Olympus, Japan). Tumor malignancy was
characterized by invasive behavior or metastasis. Expansive tumor
lesions, but with a relatively normal cytological appearance and
not showing an invasive behavior, were considered as benign or
pre-cancerous.
Hematoxylin and eosin (H&E) staining
Tissue sections on slides were deparaffinized and rehydrated and
this was followed by staining with Harris Hematoxylin (DakoCy-
tomation, Denmark) for 3,5 minutes. Sections were washed with
ddH2O and then transferred to Tris-HCl (pH 8.0) for 5 minutes.
Subsequently, the sections were stained with Eosin Y (Shandon,
Tokyo, Japan) for 30 seconds, dehydrated and then mounted.
Figure 7. Prostate tumor progression of the R26-Pten
fx/fx prostate. (A) Gross view (upper panels) and H&E staining (lower panels) of the anterior
prostate of control (at 27 weeks 4OHT post-treatment) and of R26-Pten
fx/fx mice (at 4 weeks, 6 weeks and 30 weeks after 4OHT post-treatment); B,
bladder; SV, seminal vesicle; AP (encircled in upper panels), anterior prostate; Arrows indicate the invasive border of the prostate epithelium and
stroma. (B) IHC of p-AKT (Ser473) reveal the strong membranous localization of p-AKT in the BPH, PIN and prostate cancer samples of the R26-Pten
fx/fx
mice compared to the normal epithelium of the control mice. (C) IF with antibodies against CK5 (green) and CK8 (red) reveal stratification and
expansion of the basal and lumen epithelium in the BPH, PIN and prostate cancer samples of the R26-Pten
fx/fx mice compared to the normal
epithelium of the control mice. Arrows indicate the focal CK5/CK8 (K5/K8) double-positive cells.
doi:10.1371/journal.pone.0001237.g007
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the anterior prostate lobe (AP weight in mg/body weight in g) of each group (n.=3). The p value was calculated by Student’s t-test. Error bars
represent the standard derivation. (B) Dissected anterior prostates of control (Pten
fx/fx) and of R26-Pten
fx/fx mice in the absence or presence of
LY294002 for 4 weeks; these are shown as a gross view (upper panels) and with H&E staining (middle panels). IHC of p-AKT(Ser473) is shown in the
lower panels. Arrow indicates the focal positive for p-AKT in the LY294002-treated R26-Pten
fx/fx prostate.
doi:10.1371/journal.pone.0001237.g008
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immunofluorescence studies (IF)
Tissue sections were deparaffinized, rehydrated and placed in
boiling antigen retrieval buffer (DakoCytomation). Endogenous
peroxidase activity was quenched by 3% hydrogen peroxide for
5 minutes and this was followed by incubation with blocking
reagent (1% Cold Water Fish Skin Gelatin, 5% Bovine Serum
Albumin in 16 Phosphate Buffered Saline) for 1 hour at room
temperature. For IHC, the tissues sections were subsequently
incubated with primary antibodies against CD3 (ready to use;
Abcam Ltd, Cambridge, UK), B220 (1:50 dilution; Southern
Biotech, Birmingham, AL, USA;), E-cadherin (1:50 dilution;
DakoCytomation) and p-AKT(Ser473) (1:100 dilution; Cell
Signaling Technology, Beverly, MA, USA) for 1 hour at room
temperature The tissue sections was then incubated with
biotinylated-linked secondary antibody (anti-mouse/rabbit; Dako-
Cytomation) for 30 minutes and Streptavidin-HRP (DakoCyto-
mation) was added to amplify the signals. Staining was performed
using a NovaRed substrate kit (Vector Laboratories, Burlingame,
CA). The slides were counterstained for a short time with
Hematoxylin, which was followed by dehydration and then
mounting. For IF, tissues sections were incubated with primary
antibodies against PTEN (1:12500 dilution; Cascade BioScience,
Winchester, MA), cytokeratin 5 (CK5, 1:400 dilution; Abcam)
and/or cytokeratin 8 (CK8 or TROMA-1, 1:400, Developmental
Study Hybridoma Bank, University of Iowa, Iowa City, IA, USA).
Secondary antibodies (AlexaFluor 568 conjugated anti-rat IgG
against antibody to CK8 and AlexaFluor 488 conjugated anti-
rabbit IgG against antibody to CK5; Molecular Probes, Invitro-
gen) were next incubated on the slides for 1 hour and this was
followed by DAPI staining for 2 minutes. A tyramide signaling
amplification (TSA) system (kit#22 with HRP-streptavidin and
AlexaFluor 488, Invitrogen) was used to enhance the PTEN signal.
Finally, the slides were further incubated with DAPI for 2 minutes
and mounted in fluorescent mounting medium (DakoCytomation).
Flow cytometry analysis
The control or enlarged lymphoid organs (thymus and lymph
nodes) were dissected and collected in DMEM medium. These
lymphoid tissues were grounded and filtrated through cell
strainers. The cells present were counted and then centrifuged
for 5 minutes at 4uC. Then, the cell suspensions were incubated
with 2.4G2 monoclonal antibody (a gift from Dr Jeffery J.Y. Yen)
for 30 minutes on ice followed by labeling with FITC-conjugated
antibodies against CD4 (eBioscience, San Diego, CA, USA) and
PE-conjugated antibody against CD8 (eBioscience) for 15 minutes.
After washing the cell pellets twice with 1xPBS, the cells were
resuspended in 1xPBS containing Propidium Iodine (1g/ml,
eBioscience). The percentage of live cells (PI exclusive) expressing
the CD4/CD8 surface markers were analyzed by flow cytometry
(FACScalibur, Becton Dickinson, USA) using Cell Quest software.
SUPPORTING INFORMATION
Figure S1 Immunofluorescence analysis of PTEN expression.
After one week of 4OHT injection, PTEN expression was
determined using antibody against PTEN (green) and counter-
stained with DAPI (blue) in the lung and the kidney of the R26-
Pten
fx/+ and R26-Pten
fx/fx mice.
Found at: doi:10.1371/journal.pone.0001237.s001 (1.01 MB TIF)
Figure S2 R26-Pten
fx/+ malignancies. (A) H&E-stained section of
a lung cancer shows the bronchioloalveolar features found in
a R26-Pten
fx/+ male at 42 weeks post 4OHT treatment. (B) H&E-
stained section showing lung cancer metastasis in the liver of the
same mouse described in A. (C) H&E-stained section of
a mammary gland tumor showing lobular intraductal proliferation
and microinvasion patterns in a R26-Pten
fx/+ female at 52 weeks.
(D) H&E-stained section of a liver cancer showing disarrangement
of the sinusoids, trabecular or pseudoglandular features with
scattered hyaline bodies in a R26-Pten
fx/+ male at 58 weeks. High
magnification views in C and D showing mitotic figures (arrow-
heads) have been inserted (Bar, 100m). Bars in A,D, 200m. T,
tumor lesion.
Found at: doi:10.1371/journal.pone.0001237.s002 (1.91 MB TIF)
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